TY  - JOUR
AU  - Recher, Christian
AU  - Roellig, Christoph
AU  - Berard, Emilie
AU  - Bertoli, Sarah
AU  - Dumas, Pierre-Yves
AU  - Tavitian, Suzanne
AU  - Kramer, Michael
AU  - Serve, Hubert
AU  - Bornhaeuser, Martin
AU  - Platzbecker, Uwe
AU  - Mueller-Tidow, Carsten
AU  - Baldus, Claudia D.
AU  - Martinez-Cuadron, David
AU  - Serrano, Josefina
AU  - Martinez-Sanchez, Pilar
AU  - Rodriguez Arboli, Eduardo
AU  - Gil, Cristina
AU  - Bergua, Juan
AU  - Bernal, Teresa
AU  - de la Fuente Burguera, Adolfo
AU  - Delabesse, Eric
AU  - Bidet, Audrey
AU  - Pigneux, Arnaud
AU  - Montesinos, Pau
PY  - 2021
DO  - 10.1038/s41375-021-01425-9
SN  - 0887-6924
UR  - https://hdl.handle.net/10668/25507
T2  - Leukemia
AB  - The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric...
LA  - en
PB  - Springernature
KW  - Acute myeloid-leukemia
KW  - Newly-diagnosed aml
KW  - Epigenetic therapy
KW  - Elderly-patients
KW  - Early death
KW  - Azacitidine
KW  - Management
KW  - Venetoclax
KW  - Regimens
KW  - Care
TI  - Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
TY  - research article
VL  - 36
ER  -